CT Atlantic Company
CT Atlantic AG is a biotech company that specializes in developing human-derived monoclonal antibodies for cancer treatment. It was founded by Prof. Alexander Knuth, who is a pioneer in cancer immunotherapy and has a strong focus on clinical research and applications in the field of oncology. The company has exclusive licensing agreements and performs collaborative research with the University of Zurich and the Ludwig Institute for Cancer Research. It also has a network of clinicians and clinical institutions that are closely allied with these organizations. CT Atlantic AG is based in Zurich-Schlieren, Switzerland.
Total Funding:
$9M
Headquarters:
Schlieren, Zurich
Funding Status:
Early Stage Venture
Employee Number:
1-10
Investment Stage:
N/A
Last Funding Type:
Series A
Number Of Exists:
Series A
Technology:
Cancer
Investor Type:
Company
Investors Number:
1
Founded Date:
2008
Industry:
P4 Medicine